FREE delivery to all EXCLUSIVE BOOKS stores nationwide. FREE delivery to your door on all orders over R450. Excludes all international deliveries.
|
This product is either out of print or out of stock. Add it to your wishlist and we will automatically let you know if it comes back into stock. Add to Wishlist
This product is either out of print or out of stock. Add it to your wishlist and we will automatically let you know if it comes back into stock. Add to Wishlist
Formerly known as Non Alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is a long-lasting liver condition caused by having too much fat in the liver. It is closely linked with being overweight, as well as conditions such a Type 2 diabetes and heart and circulatory disease.Designed for everyday clinical use, this evidence-based guide covers the full spectrum of MASLD, from its historical evolution and pathophysiology, to diagnosis, treatment, and long-term management.It integrates the latest guidelines and therapies, including emerging agents such as resmetirom and GLP-1 agonists, and provides practical tools such as non-invasive diagnostics (FIB-4, elastography, MRI-PDFF), risk stratification algorithms, and detailed approaches for special populations including children, pregnant women, and those with cirrhosis or hepatocellular carcinoma.Emphasising a multidisciplinary and personalised care model, the book also explores public health strategies, cost-effective screening, and healthcare implications.
Formerly known as Non Alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is a long-lasting liver condition caused by having too much fat in the liver. It is closely linked with being overweight, as well as conditions such a Type 2 diabetes and heart and circulatory disease.Designed for everyday clinical use, this evidence-based guide covers the full spectrum of MASLD, from its historical evolution and pathophysiology, to diagnosis, treatment, and long-term management.It integrates the latest guidelines and therapies, including emerging agents such as resmetirom and GLP-1 agonists, and provides practical tools such as non-invasive diagnostics (FIB-4, elastography, MRI-PDFF), risk stratification algorithms, and detailed approaches for special populations including children, pregnant women, and those with cirrhosis or hepatocellular carcinoma.Emphasising a multidisciplinary and personalised care model, the book also explores public health strategies, cost-effective screening, and healthcare implications.
